The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
115 reports and counting
Abcuro Raises $66M Series D for Inclusion Body Myositis Trial
Abcuro raised a $66 million Series D led by New Leaf Venture Partners to fund a new potentially registrational study of ulviprubart in inclusion body myositis.
Electra Therapeutics Raises $183 Million in Series C - October 22, 2024
Electra Therapeutics announced $183 Million in Series C funding at a Undisclosed valuation. Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and...
Diagonal Therapeutics Raises $125M Series B | Antibody Therapeutics
Biotech startup Diagonal Therapeutics secures $125 million Series B for rare genetic disease treatments.
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Setpoint Therapeutics raises $185M Series B
Setpoint Therapeutics raises $185M in Series B. Biotech developing therapies for autoimmune diseases...
Dianthus Therapeutics raises $288M Public Offering
Dianthus Therapeutics raises $288M in Public Offering. Biopharma developing therapies for autoimmune and inflammatory diseases...
Odyssey Therapeutics raises $213M Series D
Odyssey Therapeutics raises $213M in Series D. Biopharmaceutical company focused on autoimmune and inflammatory diseases...
Abcuro raises $200M Series C at $1.5B valuation
Abcuro raises $200M in Series C at $1.5B valuation. Antibody therapeutics for autoimmune diseases...
Star Therapeutics raises $125M Series D
Star Therapeutics raises $125M in Series D. Developing antibody therapies for autoimmune and inflammatory diseases...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.